Skip to main content
MI

Module Innovations

This startup develops diagnostic devices utilizing proprietary SDSAN technology for rapid microbial detection, specifically targeting Urinary Tract Infections (UTIs) and Antimicrobial Susceptibility testing. Their solutions provide UTI results in 15 minutes and AST profiles in as little as 2 hours, enhancing the efficiency of patient care in various healthcare settings.

Founded 201465K+ followers
Updated 20 months ago

Funding

$3.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

CX
Funding rounds are not available yet.

Founders

Product

Problem

Traditional methods for diagnosing Urinary Tract Infections (UTIs) and determining Antimicrobial Susceptibility (AST) often involve lengthy lab processes, delaying appropriate treatment and potentially contributing to antimicrobial resistance. These delays can hinder efficient patient care, especially in settings where rapid results are crucial.

Solution

This startup offers rapid diagnostic solutions for UTIs and AST, leveraging proprietary SDSAN technology to significantly reduce testing times. Their USENSe platform delivers UTI results in 15 minutes, while ASTSENSe provides antimicrobial susceptibility profiles in as little as 2 hours. By providing actionable results at the point of care, their technology aims to improve UTI management, optimize treatment decisions, and combat antimicrobial resistance across various healthcare settings.

Target Audience

The primary target audience includes healthcare providers, hospitals, and clinics seeking rapid and accurate UTI diagnostics and antimicrobial susceptibility testing at the point of care.

Features

  • USENSe platform for rapid UTI detection, providing positive/negative results in 15 minutes.
  • ASTSENSe platform for rapid antimicrobial susceptibility testing, delivering AST profiles in as little as 2 hours.
  • Proprietary SDSAN technology at the core of both diagnostic platforms.
  • Point-of-care testing capabilities, enabling faster diagnosis and treatment decisions.
  • Solutions designed to work across various healthcare settings.
This profile is AI-generated and may contain inaccuracies.